Palmitoylethanolamide is an endogenous cannabinoid. Weak ligand for CB1 (Ki=23.8 µM) and CB2 (Ki=13.9 µM) receptor. Selective agonist at GPR55. Inhibits expression of fatty acid amide hydrolase (FAAH). Displays immunosuppressant and anti-inflammatory activity and reduces granuloma-induced hyperalgesia.
Research or further manufacturing use only, not for food or drug use.